HeartFlow, Inc. Insider Trading

HTFL

⊜ Compare

Last 12 months

Insiders bought $1.05M and sold $26.3M on the open market.

All of the selling was scheduled in advance under 10b5-1 plans.

Net open-market

−$25.3M

1 buy · 28 sales

Under a 10b5-1 plan

100%

of the value sold

Insiders who bought / sold

1 / 4

executives and directors

Last open-market buy

Dec 2025

Dec 16, 2025

Get an email when HTFL's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Oct 22	Campbell Rogers Chief Medical Officer	Sold10b5-1 plan	23,933	$55.01	$1.32M	9.9%	Form 4
Oct 12	John C.m. Farquhar Chief Executive Officer	Sold10b5-1 plan	38,900	$49.57	$1.93M	12%	Form 4
Sep 18	Campbell Rogers Chief Medical Officer	Sold10b5-1 plan	19,682	$50.15	987K	8.0%	Form 4
Sep 17 – 18	Vikram Verghese Chief Financial Officer	Sold10b5-1 plan 2 parts	24,345	$50.55 average	$1.23M	14%	Form 4
Sep 11 – 15	Vikram Verghese Chief Financial Officer	Sold10b5-1 plan 3 parts	34,975	$50.08 average	$1.75M	16%	Form 4
Sep 10 – 11	John C.m. Farquhar Chief Executive Officer	Sold10b5-1 plan 2 parts	38,900	$46.78 average	$1.82M	11%	Form 4
Sep 8	Vikram Verghese Chief Financial Officer	Sold10b5-1 plan	6,640	$50.03	332K	3.0%	Form 4
Sep 2 – 3	Vikram Verghese Chief Financial Officer	Sold10b5-1 plan 2 parts	33,416	$49.85 average	$1.67M	13%	Form 4
Aug 21	John C.m. Farquhar Chief Executive Officer	Sold10b5-1 plan	27,230	$50.00	$1.36M	7.0%	Form 4
Aug 18	John C.m. Farquhar Chief Executive Officer	Sold10b5-1 plan	32,676	$45.00	$1.47M	7.8%	Form 4
Aug 17	Campbell Rogers Chief Medical Officer	Sold10b5-1 plan	9,219	$41.23	380K	3.8%	Form 4
Aug 14	John C.m. Farquhar Chief Executive Officer	Sold10b5-1 plan	15,560	$39.06	608K	3.6%	Form 4
Aug 10	John C.m. Farquhar Chief Executive Officer	Sold10b5-1 plan	22,562	$28.31	639K	4.9%	Form 4
Jul 15	Campbell Rogers Chief Medical Officer	Sold10b5-1 plan	9,219	$25.72	237K	3.8%	Form 4
Jul 10	John C.m. Farquhar Chief Executive Officer	Sold10b5-1 plan	22,562	$27.75	626K	4.9%	Form 4
Jun 24	John C.m. Farquhar Chief Executive Officer	Sold10b5-1 plan	38,900	$35.00	$1.36M	7.8%	Form 4
Jun 10	John C.m. Farquhar Chief Executive Officer	Sold10b5-1 plan	22,562	$28.50	643K	4.3%	Form 4
May 18	Campbell Rogers Chief Medical Officer	Sold10b5-1 plan	9,219	$28.34	261K	3.9%	Form 4
May 11	John C.m. Farquhar Chief Executive Officer	Sold10b5-1 plan	22,562	$29.12	657K	4.2%	Form 4
Apr 28 – 30	Bain Capital Life Sciences III General Partner, LLC Large holder	SoldNo plan 4 parts	2,000,000	$29.45 average	$58.9M	19%	Form 4
Apr 10	John C.m. Farquhar Chief Executive Officer	Sold10b5-1 plan	22,562	$26.72	603K	3.9%	Form 4
Apr 1	Campbell Rogers Chief Medical Officer	Sold10b5-1 plan	64,533	$24.64	$1.59M	22%	Form 4
Mar 19	Campbell Rogers Chief Medical Officer	Sold10b5-1 plan	64,533	$25.69	$1.66M	22%	Form 4
Mar 18	John C.m. Farquhar Chief Executive Officer	Sold10b5-1 plan	9,725	$25.00	243K	1.7%	Form 4
Mar 10	John C.m. Farquhar Chief Executive Officer	Sold10b5-1 plan	12,837	$22.66	291K	2.2%	Form 4
Mar 5	Julie A Cullivan Director	Sold10b5-1 plan	9,122	$25.00	228K	25%	Form 4
Feb 12	Campbell Rogers Chief Medical Officer	Sold10b5-1 plan	65,153	$24.49	$1.6M	23%	Form 4
Feb 10	John C.m. Farquhar Chief Executive Officer	Sold10b5-1 plan	22,562	$27.46	620K	3.7%	Form 4
Feb 5	Julie A Cullivan Director	Sold10b5-1 plan	8,000	$27.32	219K	18%	Form 4
Feb 4	Bain Capital Life Sciences Investors, LLC Large holder	SoldNo plan	2,000,000	$28.05	$56.1M	16%	Form 4
Dec 16, 2025	Jeffrey C Lightcap Director	Bought	40,000	$26.34	$1.05M	0.6%	Form 4

Oct 2210b5-1 plan
Campbell Rogers
Chief Medical Officer · sold 23,933 at $55.01
$1.32M
9.9% of stake
Oct 1210b5-1 plan
John C.m. Farquhar
Chief Executive Officer · sold 38,900 at $49.57
$1.93M
12% of stake
Sep 1810b5-1 plan
Campbell Rogers
Chief Medical Officer · sold 19,682 at $50.15
987K
8.0% of stake
Sep 17 – 1810b5-1 plan
Vikram Verghese
Chief Financial Officer · sold 24,345 at avg $50.55
$1.23M
14% of stake
Sep 11 – 1510b5-1 plan
Vikram Verghese
Chief Financial Officer · sold 34,975 at avg $50.08
$1.75M
16% of stake
Sep 10 – 1110b5-1 plan
John C.m. Farquhar
Chief Executive Officer · sold 38,900 at avg $46.78
$1.82M
11% of stake
Sep 810b5-1 plan
Vikram Verghese
Chief Financial Officer · sold 6,640 at $50.03
332K
3.0% of stake
Sep 2 – 310b5-1 plan
Vikram Verghese
Chief Financial Officer · sold 33,416 at avg $49.85
$1.67M
13% of stake
Aug 2110b5-1 plan
John C.m. Farquhar
Chief Executive Officer · sold 27,230 at $50.00
$1.36M
7.0% of stake
Aug 1810b5-1 plan
John C.m. Farquhar
Chief Executive Officer · sold 32,676 at $45.00
$1.47M
7.8% of stake
Aug 1710b5-1 plan
Campbell Rogers
Chief Medical Officer · sold 9,219 at $41.23
380K
3.8% of stake
Aug 1410b5-1 plan
John C.m. Farquhar
Chief Executive Officer · sold 15,560 at $39.06
608K
3.6% of stake
Aug 1010b5-1 plan
John C.m. Farquhar
Chief Executive Officer · sold 22,562 at $28.31
639K
4.9% of stake
Jul 1510b5-1 plan
Campbell Rogers
Chief Medical Officer · sold 9,219 at $25.72
237K
3.8% of stake
Jul 1010b5-1 plan
John C.m. Farquhar
Chief Executive Officer · sold 22,562 at $27.75
626K
4.9% of stake
Jun 2410b5-1 plan
John C.m. Farquhar
Chief Executive Officer · sold 38,900 at $35.00
$1.36M
7.8% of stake
Jun 1010b5-1 plan
John C.m. Farquhar
Chief Executive Officer · sold 22,562 at $28.50
643K
4.3% of stake
May 1810b5-1 plan
Campbell Rogers
Chief Medical Officer · sold 9,219 at $28.34
261K
3.9% of stake
May 1110b5-1 plan
John C.m. Farquhar
Chief Executive Officer · sold 22,562 at $29.12
657K
4.2% of stake
Apr 28 – 30No plan
Bain Capital Life Sciences III General Partner, LLC
Large holder · sold 2,000,000 at avg $29.45
$58.9M
19% of stake
Apr 1010b5-1 plan
John C.m. Farquhar
Chief Executive Officer · sold 22,562 at $26.72
603K
3.9% of stake
Apr 110b5-1 plan
Campbell Rogers
Chief Medical Officer · sold 64,533 at $24.64
$1.59M
22% of stake
Mar 1910b5-1 plan
Campbell Rogers
Chief Medical Officer · sold 64,533 at $25.69
$1.66M
22% of stake
Mar 1810b5-1 plan
John C.m. Farquhar
Chief Executive Officer · sold 9,725 at $25.00
243K
1.7% of stake
Mar 1010b5-1 plan
John C.m. Farquhar
Chief Executive Officer · sold 12,837 at $22.66
291K
2.2% of stake
Mar 510b5-1 plan
Julie A Cullivan
Director · sold 9,122 at $25.00
228K
25% of stake
Feb 1210b5-1 plan
Campbell Rogers
Chief Medical Officer · sold 65,153 at $24.49
$1.6M
23% of stake
Feb 1010b5-1 plan
John C.m. Farquhar
Chief Executive Officer · sold 22,562 at $27.46
620K
3.7% of stake
Feb 510b5-1 plan
Julie A Cullivan
Director · sold 8,000 at $27.32
219K
18% of stake
Feb 4No plan
Bain Capital Life Sciences Investors, LLC
Large holder · sold 2,000,000 at $28.05
$56.1M
16% of stake
Dec 16, 2025
Jeffrey C Lightcap
Director · bought 40,000 at $26.34
$1.05M
0.6% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch HTFL, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Surgical & Medical Instruments & Apparatus · Pick stocks to compare with HTFL

CompareIntrinsic value

SIBNSi-Bone Inc.

$24.95+4.96%40

TMCITreace Medical Concepts, Inc.

$4.50+5.14%14

CERSCerus Corporation

$2.42+3.21%32

KIDSOrthoPediatrics Corp.

$33.51+6.69%45

LMATLemaitre Vascular Inc.

$87.89+9.04%72

STIMNeuronetics Inc.

$2.71+19.69%30

INFUInfuSystem Holdings Inc.

$13.15+2.73%59

SKINSkinHealth Systems Inc.

$11.05+6.76%42

Held by ETFs

HTFL is in 44 US ETFs. The largest of them, with HTFL's weight in each:

Spot a number that looks wrong? Check it in HTFL's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing HTFL

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.